Company intelligence / Profile preview

Cypex

Dundee, Scotland, United Kingdom

Ownership: Private
Development stage: Other

Overview

Cypex was a Scottish biotechnology company specializing in the manufacturing of recombinant drug-metabolizing enzymes (CYPs, UGTs, CES, AOX) using a patented bacterial expression system. Its products and services supported drug discovery and development by providing in vitro data on drug metabolism for regulatory applications. Cypex was acquired by BioIVT in August 2022.

Modalities: Recombinant protein
Industry: Non-Drug Biotech

Partnerships

Hypha Discovery

Beyond the preview

Go deeper on Cypex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cypex.

Explore the full profile